Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting
EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry
Sponsor: Abbott
This observational or N/A phase trial investigates Coronary Artery Disease and is currently completed. Abbott leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Apr 28, 2026 — Present [daily]
Completed
Status: Unknown → Completed
-
Sep 2025 — Apr 2026 [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Unknown Status NA
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES in the real world. The investigators will compare EES (Xience/Promus, prospective arm) with sirolimus-eluting stent (SES, Cypher, retrospective arm).
Contact Information
- Abbott
- Boston Scientific Corporation
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .